Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thompson Medical's Encare

Executive Summary

FDA told the firm in an April 13 reg letter that labeling of the vaginal contraceptive for protection against gonorrhea and other venereal disease makes Encare a new drug requiring an approved NDA for continued marketing. FDA said it is "not aware that this particular indication for use has ever been used for OTC vaginal contraceptive products marketed in the U.S. for a material time or to a material extent" or that the spermicides have been generally recognized among experts as safe and effective for such use.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS011850

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel